Andrew Powaleny is Senior Director of Public Affairs at PhRMA and leads the organizations scientific communications. Before joining PhRMA in 2015, he worked in public affairs for a small firm in Washington, DC and served as Deputy Press Secretary for the House Committee on Energy and Commerce. Andrew came to Washington, D.C. via Connecticut with a degree from Eastern Connecticut State University where he majored in public policy and government. Andrew is active as a runner and volunteer with the DC Front Runners; most recently serving on its Board of Directors for three years as co-race director. He is also a member of the NLGJA: The Association of LGBTQ Journalists and mentors students through his alumni association with The Fund for American Studies. Andrew is passionate about scientific innovation, especially for mental illness, and his heroes are the men and women of America’s biopharmaceutical research companies.
Recent Posts
ICYMI: America’s biopharmaceutical companies are taking on COVID-19
By Andrew Powaleny | March 16, 2020
The biopharmaceutical industry is taking on COVID-19, a disease caused by a novel strain of coronavirus, through research and development (R&D) into prevention and treatment, in-kind financial...
Read More
Nearly 400 cell and gene therapies in development to target a broad range of diseases
By Andrew Powaleny | March 10, 2020
In 2017, the U.S. approved its first cell and gene therapy, making the idea of altering a gene to cure or treat a disease a reality. As the increasing pace of R&D propels cell and gene therapy...
Read More
ICYMI: Continued biopharmaceutical action on COVID-19
By Andrew Powaleny | March 6, 2020
Updated 3/11/2020 This week, PhRMA and senior executives and researchers from four member companies met with key policy makers on Capitol Hill to discuss the industry’s response to COVID-19, a...
Read More
R&D Focus: New report shows nearly 600 medicines in development for pediatric patients
By Andrew Powaleny | February 13, 2020
America’s biopharmaceutical researchers are committed to studying, developing and testing medicines to meet the unique needs of pediatric patients. New treatment options for infants, children and...
Read More
ICYMI: 2019 brings innovative medicines to patients
By Andrew Powaleny | January 17, 2020
New reports from the U.S. Food and Drug Administration (FDA) show a total of 55 novel new medicines were approved in 2019. Among these, 48 were approved by the Center for Drug Evaluation and...
Read More
ICYMI: Cancer death rate declines at record levels thanks to innovative medicines
By Andrew Powaleny | January 9, 2020
Each year, the American Cancer Society estimates the number of new cancer cases and deaths that will occur in the United States. For nearly 30 years, the trend towards fewer cancer deaths has been...
Read More
R&D Focus: Four ways the biopharmaceutical industry leads in delivering new treatments and cures
By Andrew Powaleny | December 9, 2019
In recent years, rapid advances in scientific discovery have ushered in a new era of medicine, transforming our ability to treat, and in some cases cure, some of the most challenging diseases,...
Read More
Event tomorrow: Maintaining America’s leadership in access and innovation
By Andrew Powaleny | October 16, 2019
Each year, biopharmaceutical companies invest nearly $100 billion in the discovery of new treatments and cures. Despite a challenging research and development (R&D) process, consistently high...
Read More
Nearly 140 medicines in development to treat mental illness
By Andrew Powaleny | October 10, 2019
Today is World Mental Health Day, a moment where we reflect about the challenges we still face towards better treatment of mental illness and its impact on patients.
Read More
IP Explained: Understanding biopharmaceutical innovation
By Andrew Powaleny | July 30, 2019
Over the past 25 years, prescription medicines have transformed the trajectory of many debilitating diseases and conditions, including heart disease, HIV/AIDS, cancer and hepatitis C, resulting in...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
